Why the study?
Do tivortin and corvitin improve ECG-derived surrogate markers of ischemia in patients with acute and chronic ischemic heart disease?
Observational
Do tivortin and corvitin improve ECG-derived surrogate markers of ischemia in patients with acute and chronic ischemic heart disease?
Digital processing of ECG can quantitatively evaluate the cardioprotective effects of metabolic therapies like tivortin and corvitin in ischemic heart disease.
Answers are grounded in this paper and cite their sources.
ECG surrogates may detect metabolic effects in IHD; hypothesis-generating and should not change practice without RCTs.
In order to determine the cardioprotective effect of metabolic therapy, the results of the digital processing of the standard ECG using the own software "Smart ECG" with the evaluation of effects in patients with ischemic heart disease (stable angina II functional class in comparison with the group of acute Q-myocardial infarction) were analysed . The possibility of an effective quantitative evaluation of the ECG during its digital processing (digitalization) using the own software "Smart ECG" in these patient groups was proved. In comparison with the results of the study at myocardial infarction, in contrast to stable angina, tivortin reduces the SDNN index and activates a sympathetic contour. It is positive to reduce the dispersion of the QT interval when using tivortin and corvitin. Also, these drugs reduce ST segment depression in myocardial infarction, and consequently reduce the risk of ischemia and do not increase the risk of arrhythmic death. The anti-ischemic direction of the ratio of the maximum velocities of the differentiated T wave is more pronounced in tivortin than in corvitin. Quantitative evaluation of ECG with its digital processing can be recommended to increase the effectiveness of an individual approach in the treatment of patients with acute and chronic ischemic heart disease with objective cardioprotection.
No takes yet. Share an insight, caveat, or question.
Тащук et al. (2018) conducted an observational in Ischemic heart disease (stable angina and acute Q-myocardial infarction). Metabolic therapy (tivortin and corvitin) was evaluated on ECG parameters including SDNN index, QT interval dispersion, and ST segment depression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: